Calliditas Net Income Applicable To Common Shares from 2010 to 2024
| CALT Stock | USD 20.64 0.51 2.53% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -371 M | Current Value -352.5 M | Quarterly Volatility 176.2 M |
Check Calliditas Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calliditas main balance sheet or income statement drivers, such as Interest Income of 30.5 M, Depreciation And Amortization of 17.4 M or Interest Expense of 76.9 M, as well as many exotic indicators such as Price To Sales Ratio of 10.95, Dividend Yield of 0.0 or PTB Ratio of 43.63. Calliditas financial statements analysis is a perfect complement when working with Calliditas Therapeutics Valuation or Volatility modules.
Calliditas | Net Income Applicable To Common Shares |
Latest Calliditas Therapeutics' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Calliditas Therapeutics over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Calliditas Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Calliditas Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Calliditas Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (178,933,489) | |
| Coefficient Of Variation | (98.48) | |
| Mean Deviation | 156,655,719 | |
| Median | (56,912,000) | |
| Standard Deviation | 176,214,623 | |
| Sample Variance | 31051.6T | |
| Range | 467.7M | |
| R-Value | (0.80) | |
| Mean Square Error | 12070.7T | |
| R-Squared | 0.64 | |
| Significance | 0.0003 | |
| Slope | (31,498,501) | |
| Total Sum of Squares | 434722.3T |
Calliditas Net Income Applicable To Common Shares History
About Calliditas Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Calliditas Therapeutics income statement, its balance sheet, and the statement of cash flows. Calliditas Therapeutics investors use historical funamental indicators, such as Calliditas Therapeutics's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Calliditas Therapeutics investors may use each financial statement separately, they are all related. The changes in Calliditas Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Calliditas Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Calliditas Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Calliditas Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -371 M | -352.5 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Calliditas Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Calliditas Therapeutics' short interest history, or implied volatility extrapolated from Calliditas Therapeutics options trading.
Pair Trading with Calliditas Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calliditas Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calliditas Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Calliditas Stock
| 0.61 | BMY | Bristol Myers Squibb | PairCorr |
Moving against Calliditas Stock
| 0.5 | ELYM | Eliem Therapeutics Trending | PairCorr |
The ability to find closely correlated positions to Calliditas Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calliditas Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calliditas Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calliditas Therapeutics to buy it.
The correlation of Calliditas Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calliditas Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calliditas Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Calliditas Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Calliditas Therapeutics Correlation against competitors. For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Calliditas Stock analysis
When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Calliditas Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calliditas Therapeutics. If investors know Calliditas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calliditas Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 44.972 | Quarterly Revenue Growth 0.052 | Return On Assets (0.13) | Return On Equity (0.85) |
The market value of Calliditas Therapeutics is measured differently than its book value, which is the value of Calliditas that is recorded on the company's balance sheet. Investors also form their own opinion of Calliditas Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calliditas Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calliditas Therapeutics' market value can be influenced by many factors that don't directly affect Calliditas Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calliditas Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calliditas Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calliditas Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.